Citius Oncology (NASDAQ:CTOR) Shares Up 11.5% – Time to Buy?

Citius Oncology, Inc. (NASDAQ:CTOR) was up 11.5% during mid-day trading on Monday . The stock traded as high as $0.70 and last traded at $0.6913. 33,490 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 61,252 shares. The stock had previously closed at $0.62.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Oncology in a research report on Tuesday, June 16th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Citius Oncology currently has a consensus rating of “Hold” and an average price target of $6.00.

Citius Oncology Price Performance

The stock has a 50 day moving average of $0.81 and a two-hundred day moving average of $0.93. The stock has a market cap of $64.28 million, a PE ratio of -1.47 and a beta of 3.42. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.12 and a current ratio of 0.50.

Citius Oncology (NASDAQ:CTOR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.26). The business had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $7.00 million.

Institutional Investors Weigh In On Citius Oncology

Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in shares of Citius Oncology in the 3rd quarter valued at approximately $36,000. Bank of America Corp DE grew its position in Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after purchasing an additional 8,411 shares in the last quarter. IFP Advisors Inc raised its stake in Citius Oncology by 49.5% during the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock valued at $67,000 after purchasing an additional 11,000 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in Citius Oncology during the 4th quarter valued at $104,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Citius Oncology by 31.6% in the fourth quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock valued at $220,000 after purchasing an additional 52,875 shares in the last quarter. Hedge funds and other institutional investors own 70.52% of the company’s stock.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.